Alkem Laboratories Ltd. News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Alkem Laboratories Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Alkem Laboratories Ltd.
Rating: 5
Author: ICICI Securities Limited

Keep track of all breaking news and updates on Alkem Laboratories Ltd. from all sources in a single place.

Alkem Laboratories Ltd.

22 Sep 2025, 08:30PM

5544.50

0.90%

Alkem launches pertuzumab biosimilar

Business Line

Access to pertuzumab in India has remained restricted to limited HER2-postive breast cancer patients due to cost barriers, said the company

Number of FII/FPI investors increased from 535 to 551 in Jun 2025 qtr.

Alkem launches pertuzumab biosimilar for breast cancer in India

Business Standard | 22 Sep 2025, 08:07PM

Alkem Laboratories Ltd.

22 Sep 2025, 08:30PM

5544.50

0.90%

Company Update

Alkem Laboratories Ltd - 539523 - Announcement Under Regulation 30 Of SEBI LODR - Regulatory Order

BSE India

Pursuant to Regulation 30 of SEBI LODR Regulation, 2015, this is to inform you that the Company has received an order passed by the statutory authority under the Goods and Services Tax Act, 2017. The relevant disclosure is enclosed herewith.

pdf

Alkem Laboratories Ltd.

22 Sep 2025, 04:04PM

5544.50

0.90%

Company Update

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

This is to intimate you that Alkem Laboratories Limited (the 'Company') launches Pertuza, a pertuzumab biosimilar, in India for treatment of HER2-positive breast cancer. A press release in this regard is enclosed herewith.

pdf

Alkem Laboratories Ltd.

19 Sep 2025

5544.50

0.90%

CXO 1x1: Dr. Vikas Gupta, CEO

Buy: Alkem Laboratories Ltd.

Target

ICICI Securities Limited

Alkem Laboratories’ CEO, Dr. Vikas Gupta, is targeting double-digit revenue growth in the medium term, driven by strong hold in India (68% of sales), other international markets and new ventures.

Number of FII/FPI investors increased from 535 to 551 in Jun 2025 qtr.

Alkem Laboratories Ltd.

18 Sep 2025

5544.50

0.90%

Company Update

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Please find enclosed herewith the details of investor meetings scheduled to be held on 25th September, 2025, 26th September, 2025 and 30th September, 2025.

pdf

Alkem Laboratories Ltd.

17 Sep 2025

5544.50

0.90%

Company Update

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Please find enclosed herewith the details of investor meeting scheduled to be held on 22nd September, 2025.

pdf

Alkem Laboratories Ltd.

16 Sep 2025

5544.50

0.90%

Company Update

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Please find enclosed herewith the details of investor meetings scheduled to be held on 22nd September, 2025 and 25th September, 2025.

pdf

Alkem Laboratories Ltd.

09 Sep 2025

5544.50

0.90%

Company Update

Alkem Laboratories Ltd - 539523 - Announcement Under Reg 30 (LODR)- Cancellation Of Analyst / Institutional …

BSE India

In continuation to our intimation dated 03rd September, 2025, this is to inform that, the Analyst / Investor meeting as scheduled to be held on Tuesday, 09th September, 2025, has been cancelled.

pdf

Alkem Laboratories Ltd.

08 Sep 2025

5544.50

0.90%

Company Update

Alkem Laboratories Ltd - 539523 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

BSE India

Please find enclosed herewith the details of investor meetings scheduled to be held on 12th September, 2025, 17th September, 2025, 18th September, 2025, 19th September, 2025 and 23rd September, 2025.

pdf